{"id":210637,"date":"2023-07-24T17:29:08","date_gmt":"2023-07-24T17:29:08","guid":{"rendered":"https:\/\/dominiclevent.com\/blog\/?p=210637"},"modified":"2023-07-24T17:31:14","modified_gmt":"2023-07-24T17:31:14","slug":"q2-earnings-soar-but-litigation-looms-on-horizon","status":"publish","type":"post","link":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/","title":{"rendered":"Q2 Earnings Soar, But Litigation Looms On Horizon"},"content":{"rendered":"<ul>\n<li>Johnson &amp; Johnson has been ordered to pay nearly $19 million in damages by a California to a mesothelioma victim<\/li>\n<li>The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through<\/li>\n<li>The stock declined at the news, but gained 6% at the upbeat Q2 earnings report<\/li>\n<\/ul>\n<p>Big Pharma stalwart Johnson &amp; Johnson suffered a blow to its talc litigation defense when a California court determined the company must pay a 24-year-old man nearly $19 million in damages. The victim had developed cancer from a Johnson &amp; Johnson baby talcum powder, with Johnson &amp; Johnson looking to settle thousands more through the U.S. bankruptcy court.<\/p>\n<p>It was a downbeat moment for the company\u2019s share price but soon revived with a stellar earnings report for the second quarter two days later. The looming shadow of further litigation might be enough for investors to get cold feet in the long term. Let\u2019s get into the details.<\/p>\n<p><em>Healthcare stocks are down in 2023, which is another reminder that a balanced and diversified portfolio is the key to long-term success. Q.ai\u2019s <\/em><a class=\"color-link\" title=\"https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" href=\"https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" aria-label=\"Value Vault Kit\"><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Value Vault Kit<\/em><\/a><em> is one way to go about it, packaging up the companies with strong balance sheets and relatively low valuations to help you build wealth on bargain stocks.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>It\u2019s all powered by a nifty AI sidekick that does the heavy lifting with the data, predicts where the upside lies and readjusts the Kit\u2019s holdings to help you stay one step ahead. Think of it as your new investing AI copilot.<\/em><\/p>\n<p><a class=\"color-link\" title=\"https:\/\/refer.tryq.ai\/LdhQ90luCBb\" href=\"https:\/\/refer.tryq.ai\/LdhQ90luCBb\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/LdhQ90luCBb\" aria-label=\"Download Q.ai today\"><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/LdhQ90luCBb\">Download Q.ai today<\/em><\/a><em> for access to AI-powered investment strategies.<\/em><\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">What happened in the Johnson &amp; Johnson ruling?<\/h2>\n<p>In the first litigation Johnson &amp; Johnson has faced over its talcum powder in nearly two years, a California court has ruled in favor of 24-year-old plaintiff Emory Hernandez Valadez. He developed mesothelioma in the tissue around his heart, which he claimed resulted from heavy exposure to Johnson &amp; Johnson talcum powder throughout his childhood.<\/p>\n<p>The judge ruled that Hernandez was entitled to $18.8 million in damages to compensate him for medical bills and the pain and suffering caused, but he was not awarded punitive damages. The case was allowed to proceed given the rarity of Hernandez\u2019s cancer and his limited life expectancy.<\/p>\n<p>Johnson &amp; Johnson has said it will appeal the verdict, with the company\u2019s vice president of litigation, Erik Haas, calling the judgment \u201cirreconcilable with the decades of independent scientific evaluations confirming Johnson&#8217;s Baby Powder is safe, does not contain asbestos and does not cause cancer\u201d.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">How long could the litigation go on for?<\/h2>\n<p>Tens of thousands of plaintiffs have sued Johnson &amp; Johnson, alleging that the company\u2019s baby talcum powder contained life-threatening asbestos, leading to mesothelioma and ovarian cancer. The company has always maintained that the talcum powder has never contained asbestos.<\/p>\n<p>In April, Johnson &amp; Johnson subsidiary LTL Management filed for bankruptcy in New Jersey and proposed a $8.9 billion settlement for over 38,000 lawsuits and to stop new cases from being filed. The figure dwarfs the original $2 billion J&amp;J offered.<\/p>\n<p>The bankruptcy filing is part of a strategy to resolve the talc claims in bankruptcy proceedings rather than expose Johnson &amp; Johnson to massive litigation; most litigation is halted while the Chapter 11 bankruptcy proceedings ensue. The tens of thousands of plaintiffs argue the filing was done in bad faith, and the courts rejected an earlier attempt from J&amp;J to file a subsidiary for bankruptcy in January.<\/p>\n<p>In a bankruptcy court filing, Johnson &amp; Johnson said the running cost of the talcum powder litigation had so far totaled $4.5 billion &#8211; and the vast majority of claims haven\u2019t even gone ahead yet. The plaintiffs will vote on whether to accept the $8.9 billion settlement this summer, which needs a 75% majority; if they reject it, investors should expect this to rumble on for years, if not decades.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">What were Johnson &amp; Johnson\u2019s latest earnings like?<\/h2>\n<p>Despite the litigation drama, Johnson &amp; Johnson posted a decent <a class=\"color-link\" title=\"https:\/\/tryq-ai.medium.com\/earnings-season-is-in-full-swing-heres-a-calendar-so-you-can-keep-track-6db944fe292b\" href=\"https:\/\/tryq-ai.medium.com\/earnings-season-is-in-full-swing-heres-a-calendar-so-you-can-keep-track-6db944fe292b\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/tryq-ai.medium.com\/earnings-season-is-in-full-swing-heres-a-calendar-so-you-can-keep-track-6db944fe292b\" aria-label=\"earnings beat\">earnings beat<\/a> for the second quarter. The conglomerate recorded adjusted earnings per share at $2.80 on revenue of $25.5 billion, which surpassed analyst expectations. Initial predictions had come in at $2.62 a share on revenue of $24.6 billion.<\/p>\n<p>Worldwide sales were up 6.3% compared to last year&#8217;s period, with the increase down to the company\u2019s MedTech division outperforming. The arm saw a 14.7% increase in sales on an operational basis.<\/p>\n<p>Johnson &amp; Johnson also updated its full-year earnings guidance, saying it expects to reach $10.75 per share for the 2023 fiscal year. That\u2019s slightly higher than the $10.65 per share figure the company and Wall Street forecasted in April.<\/p>\n<p>In a boon for shareholders, Johnson &amp; Johnson also announced it would be letting shareholders exchange the company\u2019s shares for Kenvue shares. Consumer health business Kenvue is the company Johnson &amp; Johnson spun out at the start of this year but still retains a 90% ownership. Further details on the share-swapping scheme are yet to be announced.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">Wall Street\u2019s reaction<\/h2>\n<p>At the California court verdict, Johnson &amp; Johnson shares slid 1.5% in premarket trading on Wednesday last week, falling a further 0.2% when the markets opened. Thanks to the good news from the second-quarter earnings, Johnson &amp; Johnson pulled back the losses. The stock rose 1.3% in premarket trading last week, reaching as high as 6% during trading hours.<\/p>\n<p>As Johnson &amp; Johnson\u2019s earnings usually act as a barometer for the sector, its competitors saw a small lift to their share prices as well. Pfizer was up 0.2%; Merck rose by 0.3%, as did Bristol Myers Squibb.<\/p>\n<p>J&amp;J might have its litigation woes, but on the whole, the <a class=\"color-link\" title=\"https:\/\/tryq-ai.medium.com\/theres-a-new-alzheimer-s-drug-on-the-market-these-are-the-healthcare-stocks-to-watch-535cccac36f9\" href=\"https:\/\/tryq-ai.medium.com\/theres-a-new-alzheimer-s-drug-on-the-market-these-are-the-healthcare-stocks-to-watch-535cccac36f9\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/tryq-ai.medium.com\/theres-a-new-alzheimer-s-drug-on-the-market-these-are-the-healthcare-stocks-to-watch-535cccac36f9\" aria-label=\"healthcare\">healthcare<\/a> sector has been weak in 2023. Johnson &amp; Johnson is down 4.49% since the start of the year; Pfizer, struggling to get past its pandemic success, is down 27%. Bristol-Myers Squibb has declined 10.5% in value, while Merck and AstraZeneca have stayed flat.<\/p>\n<p>Part of the reason is the Medicare drug price negotiations passed as part of the Inflation Reduction Act. Most of Big Pharma, including Johnson &amp; Johnson, has sued the U.S. government over the move in a bid to overturn the law. A statement from the company said the pricing limits would \u201cconstrain medical innovation, limit patient access and choice, and negatively impact the overall quality of patient care\u201d.<\/p>\n<h2 class=\"subhead-embed color-accent bg-base font-accent font-size text-align\">The bottom line<\/h2>\n<p>Johnson &amp; Johnson will want to see the California case go through the appeal process as quickly as possible, lest it trigger a fresh wave of lawsuits. Wall Street might still be keen on the stock as the earnings look good, but there\u2019s a question mark hovering over the company\u2019s future. It all depends on whether a settlement can be reached &#8211; and if it can, Johnson &amp; Johnson has clearer skies ahead.<\/p>\n<p><em>Johnson &amp; Johnson\u2019s legal issues could spell trouble in the long-term. But there\u2019s little use in picking individual stocks when you can let AI help you invest. The <\/em><a class=\"color-link\" title=\"https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" href=\"https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\" aria-label=\"Value Vault Kit\"><em data-ga-track=\"ExternalLink:https:\/\/learn.tryq.ai\/blog\/value-vault-kit?utm_campaign=Forbes&amp;utm_medium=article&amp;utm_source=Forbes\">Value Vault Kit<\/em><\/a><em> from Q.ai offers a solid solution, bundling up firms boasting robust balance sheets and bargain valuations to help you capitalize on underpriced stocks.<\/em><\/p>\n<p><em>All of this magic is brought to life by a sharp AI pal that shoulders the data analysis, anticipates the areas of potential gain, and rejigs the Kit&#8217;s holdings to help ensure you&#8217;re maximizing your investment every step of the way.<\/em><\/p>\n<p><a class=\"color-link\" title=\"https:\/\/refer.tryq.ai\/sBtmjBnuCBb\" href=\"https:\/\/refer.tryq.ai\/sBtmjBnuCBb\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/sBtmjBnuCBb\" aria-label=\"Download Q.ai today\"><em data-ga-track=\"ExternalLink:https:\/\/refer.tryq.ai\/sBtmjBnuCBb\">Download Q.ai today<\/em><\/a><em> for access to AI-powered investment strategies.<\/em><\/p>\n\n<p><a href=\"http:\/\/www.bing.com\/news\/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=64be713eb8c24a0abb52d03790185d9e&amp;url=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fqai%2F2023%2F07%2F24%2Fjohnson--johnson-bankruptcy-talk-q2-earnings-soar-but-litigation-looms-on-horizon%2F&amp;c=9546497807171953705&amp;mkt=en-gb\">Source link <\/a><br \/>\n<a href=\"https:\/\/www.dominiclevent.com\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-medium wp-image-19471\" src=\"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\" alt=\"\" width=\"400\" height=\"350\" \/><\/a><\/p>\n<p><center><iframe loading=\"lazy\" src=\"https:\/\/www.google.com\/maps\/d\/u\/1\/embed?mid=1w4tN9mf5kVdBXUXTq2KvwE23NmpUzEna\" width=\"640\" height=\"480\"><\/iframe><\/center>&nbsp;<\/p>\n<p><center><iframe loading=\"lazy\" style=\"border: 0px #ffffff none;\" src=\"https:\/\/calendar.google.com\/calendar\/embed?src=sc635csnrm8h9s9lq0cad6vkss@group.calendar.google.com\" name=\"myiFrame\" width=\"600px\" height=\"3px\" frameborder=\"1\" marginwidth=\"0px\" marginheight=\"0px\" scrolling=\"no\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center>&nbsp;<\/p>\n<p><center><\/center><\/p>\n<div>\n<div><img decoding=\"async\" src=\"http:\/\/www.dominiclevent.com\/wp-content\/uploads\/2018\/06\/Business_Solicitors_London.jpg\" width=\"600\" \/><\/div>\n<p>&nbsp;<\/p>\n<div>Dominic Levent Solicitors<\/div>\n<div>Email: Enquiries@dominiclevent.com<\/div>\n<div>Phone: 020 8347 6640<\/div>\n<div>Url: https:\/\/www.dominiclevent.com<\/div>\n<div style=\"display: none;\">cash, check, credit card, invoice<\/div>\n<p>&nbsp;<\/p>\n<div><\/div>\n<div>\n<div>1345 High Rd<\/div>\n<div>London, London N20 9HR<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson has been ordered to pay nearly $19 million in damages by a California to a mesothelioma victim The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through The stock declined at the news, but gained 6% at the upbeat Q2 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Q2 Earnings Soar, But Litigation Looms On Horizon&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,5],"tags":[],"class_list":["post-210637","post","type-post","status-publish","format-standard","hentry","category-6jun21","category-news1","entry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson has been ordered to pay nearly $19 million in damages by a California to a mesothelioma victim The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through The stock declined at the news, but gained 6% at the upbeat Q2 &hellip; Continue reading &quot;Q2 Earnings Soar, But Litigation Looms On Horizon&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\" \/>\n<meta property=\"og:site_name\" content=\"Dominic Levent Solicitors Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-24T17:29:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-24T17:31:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\" \/>\n<meta name=\"author\" content=\"spainops\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"spainops\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\",\"url\":\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\",\"name\":\"Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog\",\"isPartOf\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\",\"datePublished\":\"2023-07-24T17:29:08+00:00\",\"dateModified\":\"2023-07-24T17:31:14+00:00\",\"author\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage\",\"url\":\"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\",\"contentUrl\":\"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#website\",\"url\":\"https:\/\/dominiclevent.com\/blog\/\",\"name\":\"Dominic Levent Solicitors Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dominiclevent.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254\",\"name\":\"spainops\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g\",\"caption\":\"spainops\"},\"sameAs\":[\"https:\/\/dominiclevent.com\/blog\"],\"url\":\"https:\/\/dominiclevent.com\/blog\/author\/spainops\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/","og_locale":"en_US","og_type":"article","og_title":"Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog","og_description":"Johnson &amp; Johnson has been ordered to pay nearly $19 million in damages by a California to a mesothelioma victim The company has proposed a $8.9 billion settlement to end tens of thousands of cases and stop new ones from coming through The stock declined at the news, but gained 6% at the upbeat Q2 &hellip; Continue reading \"Q2 Earnings Soar, But Litigation Looms On Horizon\"","og_url":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/","og_site_name":"Dominic Levent Solicitors Blog","article_published_time":"2023-07-24T17:29:08+00:00","article_modified_time":"2023-07-24T17:31:14+00:00","og_image":[{"url":"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg","type":"","width":"","height":""}],"author":"spainops","twitter_card":"summary_large_image","twitter_misc":{"Written by":"spainops","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/","url":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/","name":"Q2 Earnings Soar, But Litigation Looms On Horizon - Dominic Levent Solicitors Blog","isPartOf":{"@id":"https:\/\/dominiclevent.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage"},"image":{"@id":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage"},"thumbnailUrl":"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg","datePublished":"2023-07-24T17:29:08+00:00","dateModified":"2023-07-24T17:31:14+00:00","author":{"@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dominiclevent.com\/blog\/q2-earnings-soar-but-litigation-looms-on-horizon\/#primaryimage","url":"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg","contentUrl":"https:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg"},{"@type":"WebSite","@id":"https:\/\/dominiclevent.com\/blog\/#website","url":"https:\/\/dominiclevent.com\/blog\/","name":"Dominic Levent Solicitors Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dominiclevent.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254","name":"spainops","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g","caption":"spainops"},"sameAs":["https:\/\/dominiclevent.com\/blog"],"url":"https:\/\/dominiclevent.com\/blog\/author\/spainops\/"}]}},"_links":{"self":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts\/210637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/comments?post=210637"}],"version-history":[{"count":0,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts\/210637\/revisions"}],"wp:attachment":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/media?parent=210637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/categories?post=210637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/tags?post=210637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}